Member Info for jmfw

From your link:
"To accelerate the drug development, the company has established Daewoong Infion, a joint venture company, in Indonesia and is conducting a phase 1 clinical trial for DWP710."
And from this link - https://www.prnewswire.com/ae/news-releases/daewoong-pharmaceutical-acquires-halal-certification-for-easyef-through-daewoong-infion-849913108.html
"Daewoong Infion is a joint venture that Daewoong Pharmaceutical established in 2012 with the Indonesian company Infion. The joint venture completed Indonesia's first biologic plant in Surabaya and is producing and selling Epodion, which accounts for the largest market share in the Indonesian erythropoietin (EPO) drugs market."
To me, doesn't look like Avacta involved. However, think the jv with Daewoong very exciting.

AgentB, many/most people are lax & don't follow the rules; e.g. how many of us stick to the 2mtr distancing advice. On wimbledon common at the w/e bodies were out in force, & on sunday there was a market. In general distancing wasn't being adhered to, some people wore masks, many didn't. Vast majority (if not all) weren't the disadvanteged.
How many parties, raves, dinners, been reported on the news, (bet they weren't wearing masks & distancing) so I find It hardly surprising new variants spread in the population with some ease. I don't blame anyone who can't bear the rules, but until we ALL tow the same line, mutations will play the field. That's why I've been confident that that testing is here for long into the future, not just for covid, but for a range of viruses known, or as yet, unidentified.

Some 34% of trades yesterday! Also, looks like the 'bot' is, currently, still active. If the plumber is correct, another 'spike' is coming very soon.

Hedgehog, to be fair ODX has fallen some 16% in same timeframe.

So you think that was bad news today?

Agree, what appears a very positive step. Would be interesting to know why some obviously think this is bad news.

Some have just made some quick money! However, the sovereign lfd promised by the govt is imminent @ some 2m/day (eventually). Abingdon are involved, so in reality it matters not what happens with any other contract (at this time).

Richob, are you hoping the race concludes on/by 16 March?

From Mologic 24 Dec
"Considering the preliminary number of patients included so far, further studies are planned across the UK with St George’s University of London, Northumbria Healthcare NHS Foundation Trust, Imperial College London, Nottingham University Health Trust, and the Hull Royal Infirmary, with expected report findings in January 2021. The data is available on request, pending full publication of results."
Unprecedented posted following link
https://docs.google.com/viewer?url=https://www.contractsfinder.service.gov.uk/Notice/Attachment/0e2237f3-e917-4957-9711-6de1c33be75d
the Project Plan within:-
Manufacturing
1st standard product made 28 dec
start significant volumes 19 apr
first automation pack 8 feb

Lateral Flow
complete detailed scale up 30 nov
complete ordering of priority prod for 2m test/day 30 nov
pre scale prod testing with selected uk mfrs 31 jan

Can't see how mologic can be involved. Might be avacta!!??

MB, still can't figure out why you post on here if not invested. What do you care whether or not avacta is succesful. You are blind to it's promise & concentrate on on any perceivable negative. Lots of research out there suggesting affimers are a superior product, in fact Astrea stated -
"Affimer reagents are high-performance proteinaceous ligands that have been engineered for a wide range of applications as superior alternatives to antibody-based ligands. They can be used to selectively bind difficult targets, even where antibodies and aptamers have shown limitations. In combination with our proven Mimetic Ligand® chemical ligand libraries, the Affimer ligand platform significantly expands our capacity to discover, develop and deliver custom affinity adsorbents for purification of biotherapeutics and advanced therapies."
However, think you have hit the nail on the head when referring to licensing out the affimer. We will do, & the promise of that is just as overwhelming as opportunities in which avacta will be involved directly.

Interesting (to me) that shorts had reduced their position between 12 Jan to 19 Jan (34% to 15%). Yesterday's action led me to believe they were closing such positions, however, the reverse seems to be the case - at close shorts were some 37%. If we do get the news anticipated there could well be another frenetic day where some will, again, be 'spiked'.

My guess is tlsa shorts settling (creating demand), uk buyers of tlsa selling, then reinvesting in tils.

Understatement at this moment. Have noted the short positions have gradually unwound & they could be history at this rate.

Not technical, but this looks like a good test. Anyone with a view on it (monkshood, gmcc, chiron ab8 etc).
https://www.medicaldevice-network.com/news/uk-excalibur-covid-19-antigen-test/

My own thoughts so totally agree. For all forms of international travel Covid testing will be around for a long time. But, also, tests will be developed for a range of viruses as & when they appear, & from what we are told proprietry affimers can be identified & produced very (relatively) quickly.
If avacta get this right, whether as a colloboration or independently, ................................................

Wyndrum (12:46) you are too optimistic. Why does it have to have an endpoint? 'Flu' hasn't, so why should covid? It functions well in all environments & is not dependent on time of year. Wouldn't surprise if it became endemic as unlikely the world's population will (eventually) be vaccinated. People will be travelling country to country (eg brazil - japan), so unless covid is eradicated worlwide, it will, in one form or another, be around for a long long time.

Very likely Richob, & why wouldn't it be able to develop multiple highly infectious variations/mutations. It's shown here & SA what it's capable of, so why not anywhere/everywhere. In one form or another think this virus is going to be around a long time.

For info I posted a link to his linkedin profile earlier. On there he includes his cv according to which he is (still) on contract at Pharmaxis australia. Also Pharmaxis list him as a non ex director http://www.pharmaxis.com.au/about/corporate-directory/

Not gardening leave according to his linkedin profile. His cv is listed there: https://www.linkedin.com/in/neil-graham-236769/

Nasdaq has been constantly behind AIM. I think the peak there was +/- $16.80 while AIM was +/-£3. Considering 5 for 1 adr equates to $3.36. Nasdaq will become very interesting when/if very positive news is released on any of tils product lines, or, with concrete interest from third parties, or, when 'shorts' finally decide to close. Any 2 would probably have a explosive effect. Whatever happens in due course, those issued with accustem shares have added value.